<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04284033</url>
  </required_header>
  <id_info>
    <org_study_id>52526</org_study_id>
    <nct_id>NCT04284033</nct_id>
  </id_info>
  <brief_title>Evaluation of Extended Wear Infusion Set With 670G Hybrid Closed-Loop Therapy</brief_title>
  <official_title>Evaluation of Extended Wear Infusion Set With 670G Hybrid Closed-Loop Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial to determine if an extended wear infusion set can be worn for up&#xD;
      to 7 days with a hybrid closed-loop system in adult with Type 1 Diabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare use of a standard infusion set with an extended wear infusion set.&#xD;
      Subjects will be asked to wear both types of sets twice for up to 7 days, alternating wear of&#xD;
      set type over 4 weeks. The order of infusion set wear will be randomized with the first set&#xD;
      wear. The investigators aim to see whether there is a benefit to using an extended wear&#xD;
      infusion set.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Change of sponsor and trial design&#xD;
  </why_stopped>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Actual">April 20, 2018</completion_date>
  <primary_completion_date type="Actual">November 10, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of infusion set failures due to &quot;unexplained hyperglycemia&quot;</measure>
    <time_frame>14 days for each type of infusion set, with each type of infusion set worn twice</time_frame>
    <description>Defined as:&#xD;
Glucose &gt;250 mg/dL with failure of a correction dose to lower the glucose by 50 mg/dL&#xD;
Ketones ≥0.6 mg/dL with a glucose reading of &gt;250 mg/dL (in the absence of illness)&#xD;
Evidence of infection at the infusion site (erythema or induration &gt;1cm in diameter)&#xD;
Pump occlusion alarm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of infusion set wear</measure>
    <time_frame>14 days for each type of infusion set, with each type of infusion set worn twice</time_frame>
    <description>The maximum number of days that 75% of the infusion sets are still working, excluding those that kinked on insertion or were accidentally pulled out.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Standard then Extended Infusion Set</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will start with wearing the standard infusion set for up to 7 days, then switch to the Extended Wear infusion set for up to 7 days, then repeat the cycle for a total of 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended then Standard Infusion Set</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will start with wearing the Extended Wear infusion set for up to 7 days, then switch to the standard infusion set for up to 7 days, then repeat the cycle for a total of 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extended Wear Infusion Set</intervention_name>
    <description>For two of the 4 weeks, the Extended Wear insulin infusion set will be used</description>
    <arm_group_label>Extended then Standard Infusion Set</arm_group_label>
    <arm_group_label>Standard then Extended Infusion Set</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Infusion Set</intervention_name>
    <description>For two of the 4 weeks, the standard insulin infusion set will be used</description>
    <arm_group_label>Extended then Standard Infusion Set</arm_group_label>
    <arm_group_label>Standard then Extended Infusion Set</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of type 1 diabetes for more than one year, using an insulin&#xD;
             infusion pump for at least 6 months, and using the 670G pump for at least 3 months&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Using Novolog or Humalog insulin at time of enrollment&#xD;
&#xD;
          4. For females, not currently known to be pregnant&#xD;
&#xD;
          5. An understanding of and willingness to follow the protocol and sign the informed&#xD;
             consent&#xD;
&#xD;
          6. Willing to have photographs taken of their infusion sites&#xD;
&#xD;
          7. Willing to download their 670G pump every week to a research Carelink account&#xD;
&#xD;
          8. Willing to submit a brief online questionnaire at the time of any infusion set failure&#xD;
&#xD;
          9. Able to understand spoken or written English&#xD;
&#xD;
         10. Hemoglobin A1c &lt;8.5% at the time of enrollment&#xD;
&#xD;
         11. Willing to perform three or more fingerstick glucose measurements each day&#xD;
&#xD;
         12. Willing to sign a consent for release of medical information at the time of enrollment&#xD;
&#xD;
         13. Willing to change their infusion pump insulin reservoirs at least every 6 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypoglycemic seizure or loss of consciousness in the past 6 months&#xD;
&#xD;
          2. Severe episode of DKA in the 6 months prior to study enrollment that was unrelated to&#xD;
             an infusion set failure&#xD;
&#xD;
          3. A known cardiovascular disease&#xD;
&#xD;
          4. Active proliferative diabetic retinopathy&#xD;
&#xD;
          5. Known tape allergy&#xD;
&#xD;
          6. Current treatment for a seizure disorder&#xD;
&#xD;
          7. Cystic fibrosis&#xD;
&#xD;
          8. Active infection&#xD;
&#xD;
          9. A known medical condition that in the judgment of the investigator might interfere&#xD;
             with the completion of the protocol&#xD;
&#xD;
         10. Inpatient psychiatric treatment in the past 6 months&#xD;
&#xD;
         11. Presence of a known adrenal disorder&#xD;
&#xD;
         12. If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of&#xD;
             stability on the medication for the last 2 months prior to enrollment in the study&#xD;
&#xD;
         13. Abuse of alcohol&#xD;
&#xD;
         14. History of dialysis, renal failure or known eGFR &lt;60 ml/min/1.73m2&#xD;
&#xD;
         15. Has received a blood transfusion or required treatment for anemia in the three months&#xD;
             prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Buckingham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 22, 2020</study_first_submitted>
  <study_first_submitted_qc>February 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Bruce Buckingham</investigator_full_name>
    <investigator_title>Professor Emeritus, Pediatrics - Endocrinology and Diabetes</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

